Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
This treatment can also reduce water weight gain and help the body breakdown fat and carbohydrates
Observational studies and some ophthalmology commentaries have been more reassuring overall, suggesting that many patients taking semaglutide do not experience clinically meaningful retinal worsening
control, 918) on the number of follicles revealed no significant effect following the intervention (weighted mean difference (WMD): 010
Its targeted mechanism makes it relevant in studies focused on weight management and metabolic health
The good news is that regulators are taking actions to address these problems